Please ensure Javascript is enabled for purposes of website accessibility

Why Infinity Pharmaceuticals Is Skyrocketing Today

By Prosper Junior Bakiny - Feb 11, 2021 at 12:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported results from a clinical study.

What happened?

Shares of biotech company Infinity Pharmaceuticals (INFI -6.19%) are soaring through the roof on Thursday following the company's release of data from a phase 2 clinical trial for one of its pipeline candidates. As of 12:03 p.m. EST, the drugmaker's stock was up by 21%, after jumping by as much as 51.4% earlier today.

So what

The trial in question investigated the safety and efficacy of the combination of Infinity Pharmaceuticals' eganelisib with nivolumab (a cancer treatment marketed as Opdivo by Bristol Myers Squibb) in patients with advanced urothelial cancer. During the study, the combination therapy demonstrated an increased immune activation and a decreased immune suppression compared to treatment with nivolumab alone.

The results were even more pronounced for PD-L1 negative patients (PD-L1 is a type of protein), which is an important factor. According to the lead study investigator Piotr Tomczak, PD-L1 low patients "represent the majority of metastatic urothelial cancer population." The combination of eganelisib and nivolumab was also well tolerated at the 30 mg once per day dose; during the study, the median average daily dose was 31.5 mg.

Hand drawing upward-bound graph.

Image source: Getty Images.

Now what

Shares of small-cap biotech companies such as Infinity Pharmaceuticals often skyrocket due to positive results from clinical trials. However, it is important for investors with a long-term mindset to exercise extreme caution. Despite the impressive data the healthcare company presented, there is still a long road ahead before this combination treatment gets the regulatory nod, that is, if it makes it that far at all. In the meantime, a lot can happen to derail the plans of Infinity Pharmaceuticals, including negative results from other clinical trials for some of its other programs. With those risks in mind, it might be best to stay a safe distance away from this drugmaker for now. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Infinity Pharmaceuticals, Inc. Stock Quote
Infinity Pharmaceuticals, Inc.
INFI
$0.63 (-6.19%) $0.04
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$77.00 (-0.95%) $0.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.